company background image
2F5 logo

Scinai Immunotherapeutics DB:2F5 Stock Report

Last Price

€3.16

Market Cap

€2.7m

7D

-1.9%

1Y

-43.1%

Updated

25 Dec, 2024

Data

Company Financials

Scinai Immunotherapeutics Ltd.

DB:2F5 Stock Report

Market Cap: €2.7m

2F5 Stock Overview

A development stage biopharmaceutical company, focuses on developing, manufacturing, and commercializing products for the prevention and treatment of infectious and autoimmune diseases in Israel. More details

2F5 fundamental analysis
Snowflake Score
Valuation2/6
Future Growth0/6
Past Performance3/6
Financial Health4/6
Dividends0/6

My Notes

Capture your thoughts, links and company narrative

Scinai Immunotherapeutics Ltd. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Scinai Immunotherapeutics
Historical stock prices
Current Share PriceUS$3.16
52 Week HighUS$7.30
52 Week LowUS$2.50
Beta2.36
1 Month Change-4.24%
3 Month Change2.60%
1 Year Change-43.06%
3 Year Change-98.44%
5 Year Change-99.56%
Change since IPO-99.44%

Recent News & Updates

Recent updates

Shareholder Returns

2F5DE BiotechsDE Market
7D-1.9%-0.8%-1.6%
1Y-43.1%-13.0%6.8%

Return vs Industry: 2F5 underperformed the German Biotechs industry which returned -13.2% over the past year.

Return vs Market: 2F5 underperformed the German Market which returned 6.8% over the past year.

Price Volatility

Is 2F5's price volatile compared to industry and market?
2F5 volatility
2F5 Average Weekly Movement9.5%
Biotechs Industry Average Movement6.9%
Market Average Movement4.9%
10% most volatile stocks in DE Market11.6%
10% least volatile stocks in DE Market2.4%

Stable Share Price: 2F5's share price has been volatile over the past 3 months compared to the German market.

Volatility Over Time: 2F5's weekly volatility has decreased from 22% to 10% over the past year, but is still higher than 75% of German stocks.

About the Company

FoundedEmployeesCEOWebsite
200331Amir Reichmanwww.scinai.com

Scinai Immunotherapeutics Ltd., a development stage biopharmaceutical company, focuses on developing, manufacturing, and commercializing products for the prevention and treatment of infectious and autoimmune diseases in Israel. It has licensing and collaboration agreement with Max Planck Society and University Medical Center Göttingen for the development and commercialization of COVID-19 nanosized antibody (NanoAb); and development and commercialization of NanoAbs for various other disease indications. The company was formerly known as BiondVax Pharmaceuticals Ltd.

Scinai Immunotherapeutics Ltd. Fundamentals Summary

How do Scinai Immunotherapeutics's earnings and revenue compare to its market cap?
2F5 fundamental statistics
Market cap€2.75m
Earnings (TTM)€4.52m
Revenue (TTM)€434.78k

0.6x

P/E Ratio

6.3x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
2F5 income statement (TTM)
RevenueUS$452.00k
Cost of RevenueUS$865.00k
Gross Profit-US$413.00k
Other Expenses-US$5.11m
EarningsUS$4.70m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)5.51
Gross Margin-91.37%
Net Profit Margin1,038.94%
Debt/Equity Ratio2.8%

How did 2F5 perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/25 08:13
End of Day Share Price 2024/12/23 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Scinai Immunotherapeutics Ltd. is covered by 3 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Nathan WeinsteinAegis Capital Corporation
David BautzZacks Investment Research Inc.
David BautzZacks Small-Cap Research